Takeda’s Millennium Seeks Modest Acquisitions, But Could Go Bigger
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical has freed its U.S.-based Millennium biotech unit to seek its own mergers and acquisitions among the more modest players in the drug making industry. CEO Deborah Dunshire said in an interview that Millennium is not likely to try to acquire a large company, noting Takeda's own avoidance of such deals. She said a Millennium M&A is likely to center on "smaller, single-product acquisitions." She did not, however, rule out a larger transaction as big as the $10 billion range. (Click here for more - a subscription may be required
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.